Co-Promotion Agreement Sample Contracts

Co promotion agreement for dapagliflozin
Co-Promotion Agreement • April 7th, 2023

AstraZeneca and Ono Pharmaceutical announced an agreement to co-promote dapagliflozin, an innovative once-daily oral therapy to treat type 2 diabetes mellitus in Japan.

Sample 1Sample 2Sample 3See All (34)
AutoNDA by SimpleDocs
Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. April 30, 2007 Lou Ferrari Vice President, Sales Ortho Biotech Inc. 430 Route 22 East Bridgewater, New Jersey...
Co-Promotion Agreement • August 8th, 2007 • Millennium Pharmaceuticals Inc • Pharmaceutical preparations
Sample 1Sample 2Sample 3See All (33)
JUNE 25, 2007
Co-Promotion Agreement • August 9th, 2007 • Critical Therapeutics Inc • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (4)
EX-10.50 2 dex1050.htm CO-PROMOTION AGREEMENT Portions of this exhibit marked [*] are requested to be treated confidentially. CO-PROMOTION AGREEMENT
Co-Promotion Agreement • May 5th, 2020 • Delaware

This CO-PROMOTION AGREEMENT (this “Agreement”), dated March 2, 2005, is entered into by and between SALIX PHARMACEUTICALS, INC., a California corporation (“Salix”) and ALTANA PHARMA US, INC., a Delaware corporation (“Altana”).

Sample 1Sample 2Sample 3
CO-PROMOTION AGREEMENT by and between TYME TECHNOLOGIES, INC. And EAGLE PHARMACEUTICALS, INC. January 7, 2020
Co-Promotion Agreement • May 22nd, 2020 • Tyme Technologies, Inc. • Pharmaceutical preparations • Delaware

This Co-Promotion Agreement (this “Agreement”) is entered into and dated as of January 7, 2020 (the “Effective Date”) by and between Tyme Technologies, Inc., a Delaware corporation (“TYME”), and Eagle Pharmaceuticals, Inc., a Delaware corporation (“Eagle”). TYME and Eagle are each referred to individually as a “Party” and together as the “Parties”.

Sample 1Sample 2Sample 3
Co-promotion agreement for Exenatide once-weekly
Co-Promotion Agreement • November 8th, 2022 • New York

First amendment to development, supply, manufacturing, licensing, promotion, and loan agreement for Exenatide once-weekly Development, supply, manufacturing, licensing, promotion, and loan agreement for Exenatide once-weekly (terminated)

Sample 1Sample 2Sample 3
EX-10.2 3 dex102.htm CO-PROMOTION AGREEMENT [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions....
Co-Promotion Agreement • May 5th, 2020

This Co-Promotion Agreement (this “Agreement”) is made and entered into effective as of January 28, 2011, by and between MAP Pharmaceuticals, Inc., a Delaware corporation having an address at 2400 Bayshore Parkway, Suite 200, Mountain View, California 94043 (“MAP”), and ALLERGAN USA, Inc., a Delaware corporation having an address at 2525 Dupont Drive, Irvine, California 92612 (“ALLERGAN”). MAP and ALLERGAN are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

Sample 1Sample 2Sample 3
EX-U.S. CO-PROMOTION AGREEMENT
Co-Promotion Agreement • March 25th, 2015 • Veracyte, Inc. • Services-medical laboratories • New York

Genzyme Corporation, with offices located at 500 Kendall Street, Cambridge, Massachusetts 02142 (hereinafter referred to as “Genzyme”)

Sample 1Sample 2Sample 3
EX-10.24 5 dex1024.htm CO-PROMOTION AGREEMENT FLUIDIGM CORPORATION and 454 LIFE SCIENCES, A ROCHE COMPANY CO-PROMOTION AGREEMENT Fluidigm Corporation 454 Life Sciences
Co-Promotion Agreement • May 5th, 2020 • Delaware
Sample 1Sample 2
EX-10.60 2 dex1060.htm CO-PROMOTION AGREEMENT Execution Copy Portions of this exhibit marked [*] are requested to be treated confidentially. CO-PROMOTION AGREEMENT
Co-Promotion Agreement • May 5th, 2020 • Delaware

This Co-Promotion Agreement (this “Agreement”) is entered into as of the 4th day of September, 2007, between Salix Pharmaceuticals, Ltd., a Delaware corporation, (hereinafter referred to as “SALIX”), and Eisai Inc., a Delaware corporation (hereinafter referred to as “EISAI”).

Sample 1Sample 2
RECITALS
Co-Promotion Agreement • August 9th, 2005 • Kos Pharmaceuticals Inc • Pharmaceutical preparations • New York
Sample 1Sample 2
CO-PROMOTION AGREEMENT THIS CO-PROMOTION AGREEMENT (the "Agreement") is made as of December 21, 1999 by and between iParty Corp., a Delaware corporation ("iParty"), with an address at 41 East 11th Street, 11th Floor, New York, New York 10003 and...
Co-Promotion Agreement • June 30th, 2000 • Iparty Corp • Services-computer integrated systems design • Delaware
Sample 1Sample 2
JCR and Sumitomo Pharma Enter into Co-Promotion Agreement in Japan for IZCARGO® I.V. Infusion 10 mg,
Co-Promotion Agreement • April 6th, 2023

JCR Pharmaceuticals Co., Ltd. (Head Office: Ashiya, Hyogo, Japan; Chairman and President: Shin Ashida; hereinafter, “JCR”) and Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; hereinafter, “Sumitomo Pharma”) announced today that they have concluded a co-promotion agreement (hereinafter, “the Agreement”) for IZCARGO® I.V. Infusion 10 mg (hereinafter, “the Product”) in Japan. This is a recombinant therapeutic for mucopolysaccharidosis type II currently sold by JCR.

Sample 1Sample 2
Confidential treatment requested under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2. The confidential portions of this exhibit have been omitted and are marked accordingly. The confidential portions have been filed separately with the Securities and...
Co-Promotion Agreement • November 2nd, 2012 • Auxilium Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

This Co-promotion Agreement (hereafter, the “Agreement”) is entered into as of May 18, 2012, by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation (“Auxilium”), and GlaxoSmithKline LLC, a Delaware limited liability company (“GSK”).

Sample 1Sample 2
CO-PROMOTION AGREEMENT
Co-Promotion Agreement • November 30th, 2016 • Eagle Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Co-Promotion Agreement (this “Agreement”) is entered into as of November 4, 2015 (the “Effective Date”), by and between Eagle Pharmaceuticals, Inc., a corporation organized under the laws of Delaware with offices at 50 Tice Blvd., Suite 315, Woodcliff Lake, NJ 07677 (“Eagle”) and Spectrum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware with offices at 11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052 (“Spectrum”). Each of Eagle and Spectrum is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”

Sample 1Sample 2
ELESTAT™ (EPINASTINE) CO-PROMOTION AGREEMENT
Co-Promotion Agreement • July 1st, 2004 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

THIS ELESTAT™ (EPINASTINE) CO-PROMOTION AGREEMENT is entered into as of December 8th, 2003 by and between ALLERGAN SALES, LLC., a Delaware limited liability company (formerly ALLERGAN SALES, INC., a Delaware corporation), having an address of 2525 Dupont Drive, Irvine, California 92612 (hereinafter referred to as “ALLERGAN”), and INSPIRE PHARMACEUTICALS, INC., a Delaware corporation, having an address of 4222 Emperor Boulevard, Suite 200, Durham, North Carolina 27703 (hereinafter referred to as “INSPIRE”).

Sample 1Sample 2
EX-10.2 2 d658391dex102.htm EX-10.2 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE...
Co-Promotion Agreement • May 5th, 2020 • New York

This Co-Promotion Agreement (this Agreement) is entered into this 27th day of June, 2013 (the “Effective Date”), by and between Valeant Pharmaceuticals North America LLC, a Delaware limited liability company (“Valeant”), and Zogenix, Inc., a Delaware corporation (“Zogenix”). Each of Valeant and Zogenix is referred to herein, individually, as a “Party” and collectively, as the “Parties.”

Sample 1Sample 2
April 9, 2013
Co-Promotion Agreement • September 20th, 2013 • Veracyte, Inc. • Services-medical laboratories

This letter (the “Amendment”), effective as of the date first indicated above (the “Amendment Date”), amends that certain Co-Promotion Agreement (the “CoPromote”) dated as of January 18, 2012 by and between Genzyme Corporation (“Genzyme”) and Veracyte, Inc. (“Veracyte”) in accordance with Section 12.11 thereto. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the CoPromote.

Sample 1Sample 2
EX-10 2 dex10.htm CO-PROMOTION AGREEMENT THE REGISTRANT HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN PROVISIONS OF THIS EXHIBIT WITH THE SECURITIES AND EXCHANGE COMMISSION. THE CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE BRACKETED AND MARKED WITH...
Co-Promotion Agreement • May 5th, 2020 • New York

This Agreement is made as of the 11TH day of April, 2005 (the “Effective Date”), by and between Auxilium Pharmaceuticals, Inc., a Delaware corporation, with principal offices at 160 W. Germantown Pike, Norristown, PA 19401 (“Auxilium”) and Oscient Pharmaceuticals Corp., a Massachusetts corporation, with principal offices at 1000 Winter Street, Suite 2200, Waltham, MA, 02451, (“Oscient”) (with each of Auxilium and Oscient referred to herein individually as a “Party” and collectively as the “Parties”).

Sample 1Sample 2
Contract
Co-Promotion Agreement • October 27th, 2010 • Zogenix, Inc. • Pharmaceutical preparations • New York

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

Sample 1Sample 2
EX-10.1 2 d708097dex101.htm EX-10.1
Co-Promotion Agreement • May 5th, 2020 • New York

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

Sample 1Sample 2
CO-PROMOTION AGREEMENT
Co-Promotion Agreement • March 16th, 2020 • Tetraphase Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of March 15, 2020 (the “Effective Date”) by and between ACELRX PHARMACEUTICALS, INC., a Delaware corporation, having an address of 351 Galveston Drive, Redwood City, California 94063 (hereinafter referred to as “AcelRx”), and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation, having an address of 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472 (hereinafter referred to as “Tetraphase”). AcelRx and Tetraphase are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

Sample 1Sample 2
AutoNDA by SimpleDocs
Co-promotion agreement for Enablex (darifenacin) for over activebladder treatment - terminated
Co-Promotion Agreement • May 28th, 2021
Sample 1Sample 2
AMENDMENT NO. 2
Co-Promotion Agreement • March 4th, 2003 • Medimmune Inc /De • Biological products, (no disgnostic substances) • California

This Amendment No. 2, effective on the last date of signature, modifies and amends the Co-Promotion Agreement dated effective November 26, 1997, as amended by the Amendment last executed on July 31, 2000 (together, the "AGREEMENT"), by and between Abbott Laboratories through its Ross Products Division ("ABBOTT"), and MedImmune, Inc. ("MEDIMMUNE").

Sample 1
CO-PROMOTION AGREEMENT between VIVUS and KADMON Dated as of June 1, 2015
Co-Promotion Agreement • June 10th, 2016 • Kadmon Holdings, LLC • Pharmaceutical preparations • Delaware

THIS CO-PROMOTION AGREEMENT (this “Agreement”) is made and entered into as of June 1, 2015 (the “Effective Date”) by and between VIVUS, a company organized under the laws of the state of Delaware (“VIVUS”) and KADMON, a company organized under the laws of the state of Delaware (“KADMON”). Each of VIVUS and KADMON is referred to individually as a “Party,” and collectively, as the “Parties.”

Sample 1
CO-PROMOTION AGREEMENT
Co-Promotion Agreement • November 2nd, 2007 • Santarus Inc • Pharmaceutical preparations • New York

This Co-Promotion Agreement (this “Agreement”) is entered into this 24th day of August, 2007, by and between C.B. Fleet Company, Incorporated, a Virginia corporation, and its subsidiary C.B. Fleet Investment Corporation, a Delaware corporation (collectively “Fleet”) and Santarus, Inc., a Delaware corporation (“Santarus”).

Sample 1
Co-promotion agreement for MassARRAY DX clinical diagnostics technology
Co-Promotion Agreement • July 3rd, 2024

Agena Bioscience announced a co-promotion agreement leveraging its MassARRAY DX clinical diagnostics technology with HeartGenetics' CE-IVD marked products for cardiovascular testing.

Sample 1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CO-PROMOTION AGREEMENT by and between...
Co-Promotion Agreement • March 24th, 2023 • Provention Bio, Inc. • Pharmaceutical preparations • Delaware

This CO-PROMOTION AGREEMENT (this “Agreement”) is entered into as of October 4, 2022 (the “Effective Date”) by and between Provention Bio, Inc., a corporation organized and existing under the laws of Delaware, with its principal business address at 55 Broad Street, 2nd floor, Red Bank, NJ 07701, USA (“Provention”) and Genzyme Corporation, a corporation organized under the laws of the Commonwealth of Massachusetts, with its principal business address at 450 Water Street, Cambridge MA 02141, USA (“Sanofi”). Sanofi and Provention are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”

Sample 1
Merck KGaA and BeiGene Collaborate in Co-Promotion Agreement
Co-Promotion Agreement • February 5th, 2021

BeiGene and Merck KGaA, a top big pharma company have entered into a global licensing, co-development, co-promotion and commercialization agreement for BeiGene-283.

Sample 1
CO-PROMOTION AGREEMENT
Co-Promotion Agreement • November 9th, 2006 • Depomed Inc • Pharmaceutical preparations • California

This Co-Promotion Agreement (this “Agreement”) is entered into this 24th day of July, 2006 by and between Depomed, Inc., a California corporation (“Depomed”), and Esprit Pharma, Inc., a Delaware corporation (“Esprit”).

Sample 1
AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT
Co-Promotion Agreement • August 1st, 2013 • Cubist Pharmaceuticals Inc • Pharmaceutical preparations

This AMENDMENT NO. 1 TO CO-PROMOTION AGREEMENT (the “Amendment”) is entered into on July 30, 2013 (the “Amendment Effective Date”), by and among Cubist Pharmaceuticals, Inc. (“Cubist”) and Optimer Pharmaceuticals, Inc. (“Optimer”). Cubist and Optimer may each be referred to herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment have the meaning set forth in the Agreement.

Sample 1
CERTAIN INFORMATION HAS BEEN OMITTED IN ACCORDANCE WITH ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE MARKED [***]. CO-PROMOTION...
Co-Promotion Agreement • May 7th, 2024 • Heron Therapeutics, Inc. /De/ • Pharmaceutical preparations

THIS CO-PROMOTION AGREEMENT (the “Agreement”) is dated this 5th day of January, 2024, but effective as of January 1, 2024 (the “Effective “Date”) by and between Heron Therapeutics, Inc., a Delaware corporation (hereinafter called “Heron”) and Crosslink Network, LLC, a Georgia limited liability company (hereinafter called “Co-Promoter”) (Heron and Co-Promoter sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”).

Sample 1
EXECUTION COPY
Co-Promotion Agreement • August 9th, 2012 • Zogenix, Inc. • Pharmaceutical preparations • New York

This Co-Promotion Agreement (this “Agreement”) is made as of June 6, 2012 (the “Effective Date”), by and between Zogenix, Inc., a Delaware corporation (“Zogenix”), and Mallinckrodt LLC, a Delaware limited liability company (“Mallinckrodt”). Each of Zogenix and Mallinckrodt is referred to herein, individually, as a “Party” and, collectively, as the “Parties.”

Sample 1
FIRST AMENDMENT TO THE CO-PROMOTION AGREEMENT BETWEEN VERNALIS DEVELOPMENT LIMITED AND ENDO PHARMACEUTICALS INC. DATED JULY 1, 2005
Co-Promotion Agreement • December 29th, 2005 • Endo Pharmaceuticals Holdings Inc • Pharmaceutical preparations

This First Amendment to the Co-Promotion Agreement by and between Vernalis Development Limited (“Vernalis”) and Endo Pharmaceuticals Inc. (“Endo”) (the “First Amendment”) is effective as of December 12, 2005.

Sample 1
Endo Pharmaceuticals Inc. February 19, 2008
Co-Promotion Agreement • February 26th, 2008 • Endo Pharmaceuticals Holdings Inc • Pharmaceutical preparations
Sample 1
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!